About PreOmics - The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.

Learn! PreOmics® solutions are also suitable for your targeted protein degradation research

Explore these publications to discover how iST-based proteomics sample preparation supports targeted protein degradation (TPD) research.

iST-NHS kits as part of the discovery of non-covalent DCAF1-based PROTACs
that mediate degradation of tyrosine kinases


Schröder etal., NatureCommunications,2024
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

DCAF1 PROTACs mediate the degradation of tyrosine kinases localized in the plasma membrane, cytosol as well as nucleoplasm. Proteomic profiling of HEK293T and TMD8 cells treated with DDa-1 and DCAF1 binders confirmed downregulation of CSK and LIMK2 kinases and resulted in discovery of two new non-receptor tyrosine kinases (TEC and TNK2). Cells treated with the different degraders were prepared for the TMT-based quantitative profiling using the iST-NHS kit from PreOmics®.

Read the publication

Fully automated iST-NHS kits support discovery of NVP-DKY709, a selective IKZF2 (Helios) glue degrader in cancer


Bonazzi et al., Cell Chem. Biol, 2023
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy

Cereblon (CRBN) selectivity is re-directed by glue degrader NVP-DKY709 in Treg cells. Deficiency of IKZF2 (Helios) transcription factor reduces tumor growth in mice. Quantitative proteomics profiling of Jurkat T cells treated for 16 h with NVP-DKY709 (or DMSO as control) revealed significant downregulation of IKZF2. Cell samples for this approach were prepared using the iST-NHS kit from PreOmics® on the PreON automation platform.

Read the publication
Imagine
Applying the science
Find out more about the wide range of applications to which PreOmics technology has been successfully applied